{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:33:26Z","timestamp":1793694806411,"version":"4.5.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.coviro.2022.101279","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T12:22:45Z","timestamp":1668687765000},"page":"101279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy"],"prefix":"10.1016","volume":"57","author":[{"given":"Annelies","family":"Stevaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Groaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-9302","authenticated-orcid":false,"given":"Lieve","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2022.101279_bib1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2022.101279_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2022.101279_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","article-title":"Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics","volume":"3","author":"Mazur","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coviro.2022.101279_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2022.101279_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2022.101279_bib6","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib7","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1128\/JVI.02349-15","article-title":"Investigating the influence of ribavirin on human respiratory syncytial virus RNA synthesis by using a high-resolution transcriptome sequencing approach","volume":"90","author":"Aljabr","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101279_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.coviro.2022.101279_bib9","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101279_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.coviro.2022.101279_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1592\/phco.27.4.494","article-title":"Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome","volume":"27","author":"Muller","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.coviro.2022.101279_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2022.101279_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coviro.2022.101279_bib14","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101279_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2022.101279_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2021.106652","article-title":"The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription","volume":"277","author":"Wang","year":"2021","journal-title":"Biophys Chem"},{"key":"10.1016\/j.coviro.2022.101279_bib19","article-title":"Backtracking of influenza polymerase upon consecutive incorporation of nucleoside analogue T1106 directly observed by high-resolution cryo-electron microscopy","author":"Kouba","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2022.101279_bib20","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101279_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101279_bib22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cmdc.201700116","article-title":"Synthesis of T-705-ribonucleoside and T-705-ribonucleotide and studies of chemical stability","volume":"12","author":"Huchting","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.coviro.2022.101279_sbref23","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir treatment of uncomplicated influenza in adults: results of two Phase 3, randomized, double-blind, placebo-controlled trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101279_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038463","article-title":"Influenza therapeutics in clinical practice-challenges and recent advances","volume":"11","author":"Beigel","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coviro.2022.101279_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab563","article-title":"US201 study: a Phase 2, randomized proof-of-concept trial of favipiravir for the treatment of COVID-19","volume":"8","author":"Finberg","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.coviro.2022.101279_bib26","first-page":"12575","article-title":"Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19","volume":"13","author":"Ruzhentsova","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.coviro.2022.101279_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2022.04.035","article-title":"The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies","volume":"120","author":"Hung","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101279_bib28","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1021\/acs.jmedchem.5b01933","article-title":"Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2022.101279_bib29","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1021\/acs.jmedchem.8b00617","article-title":"Prodrugs of the phosphoribosylated forms of hydroxypyrazinecarboxamide pseudobase T-705 and its de-fluoro analogue T-1105 as potent influenza virus inhibitors","volume":"61","author":"Huchting","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2022.101279_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2022.101279_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_sbref33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2022.101279_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2022.101279_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101279_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_bib37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2022.101279_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2022.101279_sbref39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coviro.2022.101279_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101279_sbref41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101279_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.coviro.2022.101279_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01719-19","article-title":"Analysis of the potential for N (4)-Hydroxycytidine to inhibit mitochondrial replication and function","volume":"64","author":"Sticher","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-D-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2022.101279_bib46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101279_bib47","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2022.101279_bib48","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol Cell"},{"key":"10.1016\/j.coviro.2022.101279_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109650","article-title":"The nucleotide addition cycle of the SARS-CoV-2 polymerase","volume":"36","author":"Bera","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2022.101279_sbref50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_sbref51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101279_bib52","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70968","article-title":"Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective","volume":"10","author":"Seifert","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.coviro.2022.101279_bib53","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2022.101279_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.coviro.2022.101279_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101279_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl8282","article-title":"Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection","volume":"14","author":"Vermillion","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2022.101279_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_sbref59","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101279_bib60","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/cid\/ciab712","article-title":"Deconstructing the treatment effect of remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: implications for critical care resource utilization","volume":"74","author":"Fintzi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2022.101279_bib61","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.coviro.2022.101279_bib62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101279_sbref63","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28113-1","article-title":"A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase","volume":"13","author":"Shannon","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101279_bib64","doi-asserted-by":"crossref","first-page":"13019","DOI":"10.1093\/nar\/gkab1160","article-title":"The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme","volume":"49","author":"Walker","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2022.101279_bib65","article-title":"Structural basis for substrate selection by the SARS-CoV-2 replicase","author":"Malone","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2022.101279_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101279_bib67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.abj5508","article-title":"4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication","volume":"375","author":"Sourimant","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101279_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib69","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101279_bib70","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101279_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2022.101279_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01925-18","article-title":"Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both nonobligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus","volume":"63","author":"Chamberlain","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2022.101279_bib73","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101279_bib74","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.7326\/M22-0729","article-title":"Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2022.101279_bib75","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1126\/science.abi9310","article-title":"Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme","volume":"373","author":"Liu","year":"2021","journal-title":"Science"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:06:51Z","timestamp":1761818811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625722000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"alternative-id":["S1879625722000906"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101279","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101279"}}